Vagina DiseaseEllele-01NCT05709119
Feasibility of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis.
An observational study of Vagina Disease and Diagnosis, run by Origin Sciences at 1 site in United Kingdom.
Trial summary
Primary Objective The primary objective is to explore the feasibility of collecting a vaginal sample using the OriCol™ Sampling Device. Secondary Objectives The study has secondary objectives to assess: 1. Acceptability of the sampling technique to both patient and clinician 2. Read more about this study
- Who is it for?
- Ages 18 to 99 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Vagina Disease, Diagnosis
- What is being tested?
- Quantification of human DNA retrieved and DNA fragmentation profile.
- How many people
- 45 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 11 Jan 2024to 31 Jul 2024
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients will be enrolled until 40 samples have been collected and confirmed assessable by the sponsor. Estimated that 45 recruits will be required to collect 40 assessable samples. For this study, 40 Participant samples will be sufficient to fulfil the objectives of the clinical study. The aim is to obtain a variety of samples from pre-, peri- and post-menopausal women to understand if the change in menopausal status affects device acceptability.
Inclusion Criteria: All participants must meet the following criteria to be eligible for the study:
- Aged 18 years or over
- Able to give voluntary, written informed consent to participate in the study
- Attending a Gynaecology Outpatient Clinic
- Undergoing vaginal speculum examination as part of their routine clinical care
Exclusion Criteria: The following exclusion criteria are applied
- Vaginal, vulval or perineal symptoms make vaginal examination inappropriate.
- Penetrative vaginal sex within the last 24 hours
- Allergy to barrier contraception
- History of allergic reactions to polypropylene and/or nitrile
- Pregnant or suspicion of pregnancy
- Participation in an interventional or pharmaceutical clinical study if treatment/intervention has already commenced
- Previously had a hysterectomy
- Previously had pelvic cancer
- Previously had chemotherapy or pelvic radiotherapy
- Currently undergoing hormone-based treatment for breast or other cancer
- Women with known Hepatitis B, Hepatitis C, HIV or HTLV-II infection, or any other similarly classified human pathogen including prion diseases (Creutzfeldt-Jakob disease).
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
The Queens Medical Research Institute
Edinburgh, Scotland, EH16 4TJ
About this study
Official title: Feasibility Study to Investigate the Use of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis.
Primary Objective
The primary objective is to explore the feasibility of collecting a vaginal sample using the OriCol™ Sampling Device.
Secondary Objectives
The study has secondary objectives to assess:
- Acceptability of the sampling technique to both patient and clinician
- To understand the balloon volume (maximum 80ml) required for effective intra-vaginal sampling.
- Participant feedback during and after the test for using the OriCol™ Sampling Device using a Visual Analogue Scale
- Patient discrete choice of Oricol™ versus speculum examination.
Read the detailed description
The female genital tract is comprised of the vagina, cervix, uterine body, fallopian tubes, and the ovaries. Studies into the dimensions of the vagina have demonstrated there is limited variation, and such variation are not significantly impacted by parity, body size or demographics. The length of the vagina differs depending on measuring techniques and whether the anterior or posterior wall is measured, but on average is between 6 - 10cm in length (OS012-TR001). Vaginal width varies significantly depending on whether this was measured at the level of the introitus, in line with the pelvic floor or more proximally within the tract. Further changes in the vagina are seen in relationship to parity.
As is found in the gastro-intestinal tract, the cervicovaginal tract is, in part, lined with mucus producing goblet cells. The mucus layer also contains shed epithelial cells, microbes and various macromolecules, including antibodies (OS012-TR002). The preliminary results of the colorectal Ori-EGI-02 study, demonstrates that human amplifiable DNA suitable for genomic and epigenetic analysis can be collected from rectal mucus samples (H. N. Humphrey et al. 2022). The rectal mucus samples are collected using the OriCol™ Sampling device, which is inserted into the rectum via a standard proctoscope and then by inflation of a nitrile membrane with 80mL of air.
The current standard examination technique used in gynaecology is a digital vaginal examination (VE) followed by speculum examination. Speculum examination may be performed in the left lateral position (using a Sims Speculum) or in lithotomy (using a Cusco's speculum). Both techniques (and variants) have been in clinical use for over 150 years and allow visual assessment of the vagina and cervix as well as allowing access for diagnostic and/or therapeutic procedures.
The current standard diagnostic investigations for cervical, endometrial, and ovarian malignancy are colposcopy, hysteroscopy, trans-abdominal and trans-vaginal ultrasonography, or CT scanning. Colposcopy requires the insertion of a bivalve speculum into the vagina to directly visualise the cervix. In outpatient hysteroscopy, speculum examination is often carried out to assess the cervix and vagina prior to the procedure. All these investigations take place within a secondary care setting.
The standard Cusco's speculum is bivalved and in the closed state has a length of 80mm and width of 22mm. The volume of the closed lubricated speculum passed into the vagina is 36.3cm3 assuming a closed cylinder. Changes in volume will occur with use. One study assessing the high-pressure zones within the vagina inflated a polyethylene bag of 10cm in length to up to 70cc volume and recorded no adverse effects during the study (OS012-TR001). This suggests that a medical device of 70cc could be inserted into the vagina for diagnostic purposes without discomfort for the patient (Jung et al. 2007)
A review was conducted of the standard Intraspec Contour speculum (Robinson Healthcare Ltd), which is supplied in three sizes: small, medium and large. This was to compare the volume and dimensions of the speculum with the OriCol™ Sampling Device membrane. Origin Sciences Limited have taken measurements of the speculums, as a specification from the manufacturer could not be located.
Due to the characteristics of membrane material of the OriCol™ Sampling Device (PS0025), the height and width of the balloon when inflated to 80ml of air can vary slightly. Inflated membrane quality control (QC) checks during manufacturing indicate that the length of the membrane should not exceed 80mm and the width 63mm. However, the average height of the inflated membrane is approximately 75.2mm and width of 41.3mm. Although the dimensions of the membrane fluctuate slightly between devices, the volume of the inflated membrane stays constant at 65cm3 when inflated with 80mls of air.
The first 40mls of air inserted from the syringe into the membrane push the deflated membrane out of the device. Air inserted above 40mls start to inflate the membrane. This data suggests that at approximate maximum volume (65cm3) the OriCol™ Sampling Device inflated membrane has a smaller volume than a small sized open speculum (~80.9cm3).
There is a current focus on reducing discomfort and increasing compliance in the ability to obtain samples of disease of the female genital tract (Campaign Against Painful Hysteroscopy: Open letter to the UK Department of Health \& Social Care (20 October 2022)). Hysteroscopy especially has been the focus on public campaigns to raise awareness of the discomfort associated with this when performed in the Outpatient Setting. Similarly discomfort during sampling of the cervix for pre-malignant change has led to interest in the development of an alternative technology, that is easier to use, has increased patient acceptability and gives a wider range of results leading to greater clinical benefit. As a minimally invasive test, it is important that it's use can be replicated easily, achieve very high levels of compliance, be extremely safe for women and deliver samples that allow high levels of analysis.
In terms of future health economic benefit, the value of the test is the potential reproducibility and ease of use in a variety of clinical settings in primary and secondary care as well as the remote environment.
This feasibility study will address the mechanics of sampling to inform on the technique used in future larger studies.
- Conditions
- Vagina Disease, Diagnosis
- Being tested
- Quantification of human DNA retrieved and DNA fragmentation profile.
- Medical subject headings
- Vaginal Diseases, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quantification of human DNA retrieved and DNA fragmentation profile.Diagnostic test
The sample will be analysed for material quality and have no impact on the patient's future care.
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary objective is to explore the feasibility of collecting an assessable vaginal sample using the OriCol™ Sampling Device.
Quantification of human DNA retrieved.
Measured: Within 3 months of completion of recruitment
Secondary outcomes (3)
Acceptability of the sampling technique to both patient and clinician
To assess both ease of use and patient acceptance
Measured: Immediate from test performance
To understand the balloon volume (maximum 80ml) required for effective intra-vaginal sampling.
Assess variation of vaginal volume and balloon inflation to sample retrieved.
Measured: Within 3 months
Participant feedback during and after the test for using the OriCol™ Sampling Device using a Visual Analogue Scale
To assess patient feedback from the test compared to the speculum examination
Measured: Immediate from test performance
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2023
- Study start11 Jan 2024
- Primary completion30 May 2024
- Study completion31 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vagina DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 45 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Origin Sciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Royal Infirmary of Edinburgh
- Responsible party
- Sponsor
- Investigators
- Andrew Horne, PhD MRCOG, Principal investigator, Edinburgh Royal Infirmary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05709119
- Sponsor's protocol ID
- Ellele-01
- Acronym
- Ellele-01
- Status last verified
- Jan 2024
- First submitted
- 24 Jan 2023
- Last updated
- 18 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study to Investigate the Use of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis.
- ClinicalTrials.gov ID
- NCT05709119
- Acronym / sponsor ID
- Ellele-01 / Ellele-01
- Conditions
- Vagina Disease, Diagnosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Origin SciencesIndustry (pharma, biotech, devices)
- Collaborators
- Royal Infirmary of Edinburgh
- Study start
- 11 Jan 2024 (actual)
- Primary completion
- 30 May 2024 (actual)
- Study completion
- 31 Jul 2024 (actual)
- First posted
- 1 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objective
The primary objective is to explore the feasibility of collecting a vaginal sample using the OriCol™ Sampling Device.
Secondary Objectives
The study has secondary objectives to assess:
- Acceptability of the sampling technique to both patient and clinician
- To understand the balloon volume (maximum 80ml) required for effective intra-vaginal sampling.
- Participant feedback during and after the test for using the OriCol™ Sampling Device using a Visual Analogue Scale
- Patient discrete choice of Oricol™ versus speculum examination.
Detailed description
The female genital tract is comprised of the vagina, cervix, uterine body, fallopian tubes, and the ovaries. Studies into the dimensions of the vagina have demonstrated there is limited variation, and such variation are not significantly impacted by parity, body size or demographics. The length of the vagina differs depending on measuring techniques and whether the anterior or posterior wall is measured, but on average is between 6 - 10cm in length (OS012-TR001). Vaginal width varies significantly depending on whether this was measured at the level of the introitus, in line with the pelvic floor or more proximally within the tract. Further changes in the vagina are seen in relationship to parity.
As is found in the gastro-intestinal tract, the cervicovaginal tract is, in part, lined with mucus producing goblet cells. The mucus layer also contains shed epithelial cells, microbes and various macromolecules, including antibodies (OS012-TR002). The preliminary results of the colorectal Ori-EGI-02 study, demonstrates that human amplifiable DNA suitable for genomic and epigenetic analysis can be collected from rectal mucus samples (H. N. Humphrey et al. 2022). The rectal mucus samples are collected using the OriCol™ Sampling device, which is inserted into the rectum via a standard proctoscope and then by inflation of a nitrile membrane with 80mL of air.
The current standard examination technique used in gynaecology is a digital vaginal examination (VE) followed by speculum examination. Speculum examination may be performed in the left lateral position (using a Sims Speculum) or in lithotomy (using a Cusco's speculum). Both techniques (and variants) have been in clinical use for over 150 years and allow visual assessment of the vagina and cervix as well as allowing access for diagnostic and/or therapeutic procedures.
The current standard diagnostic investigations for cervical, endometrial, and ovarian malignancy are colposcopy, hysteroscopy, trans-abdominal and trans-vaginal ultrasonography, or CT scanning. Colposcopy requires the insertion of a bivalve speculum into the vagina to directly visualise the cervix. In outpatient hysteroscopy, speculum examination is often carried out to assess the cervix and vagina prior to the procedure. All these investigations take place within a secondary care setting.
The standard Cusco's speculum is bivalved and in the closed state has a length of 80mm and width of 22mm. The volume of the closed lubricated speculum passed into the vagina is 36.3cm3 assuming a closed cylinder. Changes in volume will occur with use. One study assessing the high-pressure zones within the vagina inflated a polyethylene bag of 10cm in length to up to 70cc volume and recorded no adverse effects during the study (OS012-TR001). This suggests that a medical device of 70cc could be inserted into the vagina for diagnostic purposes without discomfort for the patient (Jung et al. 2007)
A review was conducted of the standard Intraspec Contour speculum (Robinson Healthcare Ltd), which is supplied in three sizes: small, medium and large. This was to compare the volume and dimensions of the speculum with the OriCol™ Sampling Device membrane. Origin Sciences Limited have taken measurements of the speculums, as a specification from the manufacturer could not be located.
Due to the characteristics of membrane material of the OriCol™ Sampling Device (PS0025), the height and width of the balloon when inflated to 80ml of air can vary slightly. Inflated membrane quality control (QC) checks during manufacturing indicate that the length of the membrane should not exceed 80mm and the width 63mm. However, the average height of the inflated membrane is approximately 75.2mm and width of 41.3mm. Although the dimensions of the membrane fluctuate slightly between devices, the volume of the inflated membrane stays constant at 65cm3 when inflated with 80mls of air.
The first 40mls of air inserted from the syringe into the membrane push the deflated membrane out of the device. Air inserted above 40mls start to inflate the membrane. This data suggests that at approximate maximum volume (65cm3) the OriCol™ Sampling Device inflated membrane has a smaller volume than a small sized open speculum (~80.9cm3).
There is a current focus on reducing discomfort and increasing compliance in the ability to obtain samples of disease of the female genital tract (Campaign Against Painful Hysteroscopy: Open letter to the UK Department of Health \& Social Care (20 October 2022)). Hysteroscopy especially has been the focus on public campaigns to raise awareness of the discomfort associated with this when performed in the Outpatient Setting. Similarly discomfort during sampling of the cervix for pre-malignant change has led to interest in the development of an alternative technology, that is easier to use, has increased patient acceptability and gives a wider range of results leading to greater clinical benefit. As a minimally invasive test, it is important that it's use can be replicated easily, achieve very high levels of compliance, be extremely safe for women and deliver samples that allow high levels of analysis.
In terms of future health economic benefit, the value of the test is the potential reproducibility and ease of use in a variety of clinical settings in primary and secondary care as well as the remote environment.
This feasibility study will address the mechanics of sampling to inform on the technique used in future larger studies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 to 99 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients will be enrolled until 40 samples have been collected and confirmed assessable by the sponsor. Estimated that 45 recruits will be required to collect 40 assessable samples. For this study, 40 Participant samples will be sufficient to fulfil the objectives of the clinical study. The aim is to obtain a variety of samples from pre-, peri- and post-menopausal women to understand if the change in menopausal status affects device acceptability.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quantification of human DNA retrieved and DNA fragmentation profile.The sample will be analysed for material quality and have no impact on the patient's future care. | Diagnostic test | – |
Primary outcome
The primary objective is to explore the feasibility of collecting an assessable vaginal sample using the OriCol™ Sampling Device.
Time frame: Within 3 months of completion of recruitment
Quantification of human DNA retrieved.
3 secondary outcomes
Acceptability of the sampling technique to both patient and clinician
Time frame: Immediate from test performance
To understand the balloon volume (maximum 80ml) required for effective intra-vaginal sampling.
Time frame: Within 3 months
Participant feedback during and after the test for using the OriCol™ Sampling Device using a Visual Analogue Scale
Time frame: Immediate from test performance
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2024.
- Individual participant dataSharing planned: No
Related trials for Vagina Disease
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
PRP for Sexual Function
Female Sexual Dysfunction, Sexual Dysfunction
Recruiting
Methylation Analyses for Gynaecological Research Through Home-based Self-sampling
Healthy Adult Participants, Gynecological Disease
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Active, not recruiting
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study
Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrew Horne, PhD MRCOG principal investigator
Edinburgh Royal Infirmary
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vagina Disease and Diagnosis, run by Origin Sciences at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary objective is to explore the feasibility of collecting an assessable vaginal sample using the OriCol™ Sampling Device. (time frame: Within 3 months of completion of recruitment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2024; AzTrials last refreshed its copy on 7 Nov 2026.